You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. movers

Piper analyst bullish on Infinity’s drug

Shares of Cambridge-based Infinity Pharmaceuticals Inc. rose after Piper Jaffray analyst M. Ian Somaiya said he believes the company’s experimental drug, IPI-145, will be approved to treat several types of cancer, with annual sales eventually approaching $3 billion. Infinity’s other drug, IPI-504, is in clinical testing as a treatment for lung cancer. The company is scheduled to report its fourth-quarter results on Tuesday. Analysts forecast a quarterly loss of 84 cents per share.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of